Abstract
Drug-induced mitochondrial dysfunction is a contributor to both late-stage compound attrition and post-market drug withdrawals. This review outlines the mechanisms which lead to drug-induced mitochondrial dysfunction and discusses the tremendous advances that have been made in the development of in vitro methods to identify mitochondrial impairment. Potentially useful animal models and in vivo methods to detect drug-induced mitochondrial impairment are also discussed.
Keywords: Mitochondrial dysfunction, oxidative phosphorylation, organ toxicity, mitochondrial diseases, drug safety, bioenergetics, mutation, metabolomics, dyslipidemia, NSAID, water, synthesis, organic
Current Drug Targets
Title: Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Volume: 12 Issue: 6
Author(s): Sashi Nadanaciva and Yvonne Will
Affiliation:
Keywords: Mitochondrial dysfunction, oxidative phosphorylation, organ toxicity, mitochondrial diseases, drug safety, bioenergetics, mutation, metabolomics, dyslipidemia, NSAID, water, synthesis, organic
Abstract: Drug-induced mitochondrial dysfunction is a contributor to both late-stage compound attrition and post-market drug withdrawals. This review outlines the mechanisms which lead to drug-induced mitochondrial dysfunction and discusses the tremendous advances that have been made in the development of in vitro methods to identify mitochondrial impairment. Potentially useful animal models and in vivo methods to detect drug-induced mitochondrial impairment are also discussed.
Export Options
About this article
Cite this article as:
Nadanaciva Sashi and Will Yvonne, Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry, Current Drug Targets 2011; 12(6) . https://dx.doi.org/10.2174/138945011795528985
DOI https://dx.doi.org/10.2174/138945011795528985 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Bioinformatics Tools for Mass Spectrometry-Based High-Throughput Quantitative Proteomics Platforms
Current Proteomics Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endocrine Therapies and QTc Prolongation
Current Drug Safety Hypocholesterolemia
Current Vascular Pharmacology Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews The Complex Biology of FOXO
Current Drug Targets LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism AMPK As A Target in Rare Diseases
Current Drug Targets Targeted Nucleic Acid Delivery to Mitochondria
Current Gene Therapy